CROI: Conference on Retroviruses and Opportunistic Infections

Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.

A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.

From innovative therapies to global care strategies, HIV experts at CROI 2026 share the breakthroughs and lessons they hope every viewer, near or far, takes home.

The Conference on Retroviruses and Opportunistic Infections 2026 included breakthrough research and looked toward the future of HIV.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.

Sweeping federal funding cuts and stalled prevention efforts are unraveling hard-won gains in HIV research and access, warns Peter Staley.

Todd Brown, MD, PhD, explains key considerations for using GLP‑1 drugs in patients with HIV, including titration tips, surgery precautions, and bone/muscle monitoring.

Presentations focused on the efficacy of long-acting cabotegravir, doravirine/islatravir, and bictegravir/lenacapavir when used as antiretroviral therapy.

Abstracts presented during the Conference on Retroviruses and Opportunistic Infections 2026 offered a glimpse into which therapies patients prefer to use to treat HIV.

At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.

The REPRIEVE study finds statins cut heart events in HIV by lowering lipids, inflammation, and hypertension risk.

A session at CROI 2026 opened with questions on how glucagon-like peptide-1 receptor agonists could be used in HIV.

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for remission without therapy.

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to improve testing and treatment access.

New research shows that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on a steady budget through PEPFAR and SNAP.

Posters presented during the Conference on Retroviruses and Opportunistic Infections 2026 highlight the safe use of tirzepatide in patients with HIV.

The first full day of CROI 2026 featured a lecture that outlined the next steps in treating and preventing HIV.

CROI 2026 highlights will include HIV prevention, long-acting treatments, and other advancements shaping research, clinical practice, and global policy.

The conference, held in Denver, Colorado, promises presentations on breaking research and the future of prevention.

Exploring caregiver dependence and social determinants of health reveals critical barriers to HIV care for children, impacting treatment adherence and access, explains Priscilla Tsondai, MD, MPH.

Lynae Darbes, PhD, discusses what her research results mean when it comes to implementation of self-testing and counselling for couples vulnerable for HIV.

An expert on the intersection of HIV and menopause, Bridgette J. Picou, LVN, ACLPN, The Well Project, explains the importance of overcoming siloed care for women living with HIV and going through menopause.

Lynae Darbes, PhD, discussed the findings of her study, which found that home-based visits helped to encourage the uptake of HIV testing.

In part 1 of this interview with Katrina Ortblad, ScD, MPH, she addressed bridging gaps in HIV care with pharmacy-based solutions.

Annie Antar, MD, PhD, spoke about how long viral clearance could be an indicator of long COVID, but more research would need to be done to confirm this.

Annie Antar, MD, PhD, discusses the association between the symptoms of long COVID and HIV status.

The Conference on Retroviruses and Opportunistic Infections 2025 (CROI) featured multiple sessions that focused on breaking research and treatments.